They changed their endpoints, too, i think. The primary endpoint of the trial of moderate COVID-19 patients originally looked at the proportion of patients dis

They changed their endpoints, too, i think. The primary endpoint of the trial of moderate COVID-19 patients originally looked at the proportion of patients discharged by day 14. The trial of severe patients was assessing the normalization of fever and oxygen saturation through day 14. Now, Gilead has changed all of those details. The trial of patients with severe COVID-19 has swelled in size from 400 subjects to 2,400 participants. Gilead dialed the enrollment target in the clinical trial of moderate COVID-19 patients up from 600 to 1,600. The trials have new primary endpoints, too. In each case, Gilead has changed the primary endpoint to focus on the odds of improvement on a seven-point scale that runs from death to not hospitalized. https://www.fiercebiotech.com/biotech/gilead-supersizes-remdesivir-trials-changes-primary-endpoint https://www.fiercebiotech.com/biotech/gilead-supersizes-remd...